Products from BPS Bioscience require a minimum order value above 400€
Applications: Positive control for anti-BCMA CAR evaluation in T cellsTransduction optimization studies
Background: B-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and on Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy because of its restricted expression in nonmalignant tissue but almost universal expression on MM cells. To date, the FDA has approved two BCMA CAR-T therapies for the treatment of multiple myeloma.
Description: The anti-BCMA CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-BCMA (clone C11D5.3) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (Figure 1). The lentiviruses also transduce a puromycin selection gene.
Formulation: The lentiviruses were produced from HEK293T cells, concentrated and resuspended in DMEM.
Storage Stability: Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the virus at -80°C.
Supplied As: 50 µl of anti-BCMA CAR at a titer ≥ 108 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-2
English
Deutsch
